A Phase 2 interventional study of Cannabis and Placebo in Alzheimer Disease, sponsored by Federal University of Latin American Integration. Completed at 1 site in Brazil. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Federal University of Latin American Integration · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Alzheimer Disease with a site in Brazil — 13 open to participants now, 18 under way, 13 of them phase 3. Alzheimer Disease · Brazil.
Among the 59 studies in Alzheimer Disease with a site in Brazil, this one is the 39th largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 in phase 2, and was the 46th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →13 of the 59 studies in Alzheimer Disease with a site in Brazil are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 7 more countries
Ages 55–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Brazil, Australia, Austria and 14 more countries
Ages 18+
Getúlio Vargas University Hospital · Sites in Brazil
Ages 65+ · Healthy volunteers
Bristol-Myers Squibb · Sites in Brazil, United States, Argentina and 23 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in Brazil, United States, Argentina and 14 more countries
Ages 60–85
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 36 · Phase 4 1
First in 1999; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 490 across the 55 interventional studies, 855 across the 4 observational. Of the 35 that completed or were terminated, 18 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 59 have an industry lead sponsor. The 10 most frequent:
Federal University of Latin American Integration is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Federal University of Latin American Integration has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Alzheimer Disease with a site in Brazil that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06733714Universidade Federal do Rio de JaneiroAssociation of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults | 2027-03-01 |
| NCT07391436Getúlio Vargas University HospitalUse of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies in Alzheimer Disease with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summary:
The objective of the study is to evaluate the effect of cannabinoids on Alzheimer's Disease. This is a double-blind, randomized, placebo-controlled clinical trial. The study aims to recruit patients of both sexes diagnosed with Alzheimer's Disease who are in the mild and moderate stages for treatment with cannabinoids.
The specific objectives of the study are:
Primary Outcome
Secondary Outcomes
Participants will use a compound containing CBD/THC 50/5 mg/mL, administered as 0.2 mL once a day. The placebo group will use a compound identical to the treatment but containing only vehicle. To address the questions above, the treated group will be compared with the placebo group over a period of 6 months. Participants will be assessed every 2 months. Additionally, blood and cerebrospinal fluid tests will be conducted to measure specific proteins related to Alzheimer's Disease and inflammatory markers.
Alzheimer's disease (AD) is closely linked to the accumulation of neurotoxins derived from Aβ and tau, leading to cognitive impairment. This project posits that an imbalance in the endocannabinoid system occurs in an AD-dependent manner. Reported connections between dementia, inflammation, Aβ, and alterations in the cannabinoid system in experimental models of AD support this hypothesis. Cannabinoids may restore baseline brain function while avoiding major side effects. Despite extensive research into new AD therapies, no significant improvement has been achieved recently, and there is little consensus on how scientists will innovate to develop a new treatment. Cannabinoid-based therapy has emerged as crucial for the treatment of many diseases considered incurable. The expected results of this project will provide important insights into the ability of cannabinoids to counteract neurochemical imbalance during AD progression, thereby improving memory performance and affecting inflammation as well as Aβ and tau levels.
The key point is to provide evidence that cannabinoids can serve as an efficient treatment for AD while avoiding major side effects. The aim of this project is to determine the effect of cannabinoids in AD patients, evaluating memory and cognition. It is expected that the results will establish that cannabinoids are critical for restoring the baseline function of the endocannabinoid system in AD brains and their beneficial effects. This project may be instrumental in validating new therapeutic approaches for AD.
To evaluate the pharmacological activity of low doses of CBD, a double-blind, randomized, placebo-controlled clinical trial will be conducted for a duration of 6 months. A baseline assessment will be performed, and patients will be evaluated every 60 days for a period of 6 months, totaling 4 evaluation sessions. For this purpose, the following questionnaires will be applied: Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Geriatric Depression Scale (GDS), Alzheimer's Disease Quality of Life version patient, version caregiver and caregiver-patient version, Cornell Depression in Dementia Scale, and Epworth Sleepiness Scale. All questionnaires are references in their assessment domains and are validated for Portuguese/Brazil. In addition to the evaluation scales, biological material will be collected with blood and cerebrospinal fluid samples at baseline and at the end (after 6 months). The following analytes will be measured in the CSF: BDNF, beta-amyloid, Tau protein, TNFα, IL-6, IL-1β, and IL-10. During the research and data collection, patients' conventional treatments will not be altered.
Statistical Analysis Plan SPSS software, version 29.0 will be used for the analyses. For quantitative data, the Shapiro-Wilk distribution test will be performed. Potential associations between qualitative variables will be analyzed using the Chi-Square test with adjusted residual analysis (χ²). The means (±SD) will be analyzed using the Student's t test for independent samples. Medians [IQR] will be calculated using the Mann-Whitney U test. Paired quantitative data will be compared individually by group across the analyzed time points using Friedman's ANOVA test.
A generalized estimating equations (GEE) model, linear or with log-gamma link, and Bonferroni correction will be used to simultaneously evaluate quantitative parameters over time and between groups. For these descriptive analyses, data will be presented as means ± standard errors (±SEM). Pearson or Spearman correlations can be performed between variables of interest. For all analyses, the significance level will be set at 5%.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive a liquid solution only with vehicle and no cannabinoid.
Other: Placebo
Patients will receive the dose of 0,2 ml of a compound contain CBD:THC (50 mg:5 mg).
Other: Cannabis
0,2 ml of CBD:THC (50 mg:5 mg)
Also known as: CBD:THC (50 mg:5 mg)
Product vehicle, medium chain triglycerides (MCT)
Mini Mental State Exam (MMSE)
scores range from 0 to 30, with higher scores indicating cognitive improvement.
Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.
Neuropsychiatric Inventory-Questionnaire (NPI-Q)
Assesses neuropsychiatric symptoms in patients with dementia. Evaluates 12 symptoms in the following domains: delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviors, nocturnal behavioral disorders, and appetite disorders. The score ranges from 0 to 144.
Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.
Geriatric Depression Scale (GDS)
Assesses depressive symptoms in the elderly. The investigators will use the short version, which has a score from 0 to 15. The higher the score, the greater the depressive symptoms.
Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.
Quality of Life in Alzheimer's Disease scale (QoL-AD)
The scale has 3 versions, one of which is applied to the patient, another to the caregiver to answer about the patient's life, and one for the caregiver to answer about their own life. The score may vary, the one the investigators will use is the sum of the questionnaires about the patient, caregiver version and patient version, with the patient version having a weight of 2. Its score varies from 13, indicating the worst possible quality of life, up to 52, and the higher the score, the higher the quality of life.
Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.
Cornell Scale for Depression in Dementia (CSDD)
Assess symptoms of depression in patients with dementia. Has 19 questions applied to caregiver and patient. The maximum score is 38 points, with scores higher than 10 indicating probable major depression and greater than 18 as major depression.
Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.
Epworth Sleepiness Scale (ESS )
Evaluates 8 items with scores ranging from 0 to 24, in which scores higher than 10 indicate sleep disturbances.
Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.
Specific markers of Alzheimer's disease: Beta-amyloid 40, beta-amyloid 42, tau protein (fraction 181), and phosphorylated tau protein
The following proteins will be quantified in the cerebrospinal fluid: beta-amyloid 40, beta-amyloid 42, tau protein (fraction 181), and phosphorylated tau protein.
Time frame: Collections will be made at the initial time, before the start of treatment and at the end time, after 180 days.
BDNF (Brain Derived Neurotrophic Factor)
It will be measured in serum or plasma
Time frame: Collections will be made at the initial time, before the start of treatment and at the end time, after 180 days.
Inflammatory markers: TNFα (Tumor Necrosis Factor alpha), IL-6 (Interleukin-6), IL-1β (Interleukin-1 beta), and IL-10 (Interleukin-10)
It will be measured in serum or plasma
Time frame: Collections will be made at the initial time, before the start of treatment and at the end time, after 180 days.
Safety Endpoints - UKU Side Effect Rating Scale
Will be conducted on patients and caregivers during all planned visits to ascertain the frequency and severity of adverse events. There will be neurological and physical examinations as well as laboratory testing.
Time frame: The participants will be evaluated before starting treatment, and then every 60 days until 180 days are complete, resulting in 4 evaluations.
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Aug 2024, 0 months.
Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's 0 months is below that.
Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal University of Latin American Integration